Tema Space Innovators ETF (NASA)
Live price chart, market sentiment, and community perspectives for Tema Space Innovators ETF (AMEX: NASA).
Live price chart, market sentiment, and community perspectives for Tema Space Innovators ETF (AMEX: NASA).
On our desk, the narrative shifted overnight once SpaceX went public. We lost that unique scarcity premium that drove NASA past $1 billion in assets in just 37 trading days. Now that investors can buy SpaceX directly, the fund's 0.75% fee is a tough sell unless you are specifically looking for diversified space-theme exposure rather than pure-play aerospace conviction.
From a risk management standpoint, the concentration is double-edged. While SpaceX, Rocket Lab, and AST SpaceMobile offer massive upside exposure to growing commercial launch activity, individual stock drawdowns like LUNR cratering 50% and FLY dropping 40% show how brutal picking individual winners can be. The fund's drift back toward its March launch lows reflects severe valuation compression across non-SpaceX holdings.
Looking at market sentiment from a macro angle, Trump's 1,000-launch goal and supportive government policies are throwing a lifeline to the sector. If these policy implementations translate into real industry changes, a 10–20% total return over the next 6 to 12 months with a near-term target of $29 looks entirely plausible, especially after a 33% reset wiped out weak hands.
Our quant models flagged an 18.2% weekly jump following pre-earnings momentum, but earnings for Rocket Lab and AST SpaceMobile are the real binary catalysts. With SpaceX representing a smaller fraction of the NAV and traditional names reporting, the correlation structure of the ETF has decoupled from pure private-market valuations into standard public market volatility.
When evaluating the portfolio mechanics, note that Tema didn't just sit on its hands during the selloff. SEC filings show they quietly built out heavy positions, adding 5.73 million shares across ASTS, RKLB, and LUNR worth roughly $320.5 million. That aggressive accumulation signals long-term conviction from the managers even as the fund tests support near $26.
Explore plasma cleansing, somatic organ swaps, and BCI.